Synthesis, calcium-channel blocking activity, and conformational analysis of some novel 1,4-dihydropyridines: Application of PM3 and DFT computational methods

Medicinal Chemistry Research

Volumn 21, Issue 10, 2012, Pages 2749-2761

  Fassihi, Afshin ^a   Mahnam, Karim ^b   Moeinifard, Behzad ^c   Bahmanziari, Maryam ^c   Aliabadi, Hojjat Sadeghi ^a   Zarghi, Afshin ^d   Sabet, Razieh ^a   Salimi, Mona ^e   Mansourian, Mahboubeh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHREKORD UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

1,4 Dihydropyridines; Conformational analysis; Density functional theory; Semi empirical

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; BIS ISOBUTYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; DICYCLOHEXYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; DICYCLOHEXYLMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; DICYCLOPENTYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; DIMETHOXYETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ETHYL BENZYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ETHYL ISOPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ETHYL METHOXYETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ETHYL PHENPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ISOPROPYL BENZYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ISOPROPYL CYCLOHEXYLMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ISOPROPYL METHOXYETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ISOPROPYL PHENPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; ISOPROPYL, TERT BUTYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; METHYL BENZYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; METHYL ETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; METHYL ISOPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; METHYL METHOXYETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; METHYL PHENPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 [2 METHYLTHIO 1 (PHENYLAMINO) 1H IMIDAZOLE 5 YL] 3,5 PYRIDINE DICARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM CHANNEL BLOCKING ACTIVITY; CONFORMATION; CONTROLLED STUDY; DENSITY FUNCTIONAL THEORY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; INFRARED SPECTROMETRY; MALE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY;

EID: 84866419007     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9807-x     Document Type: Article

References (38)

1. Amini M, Golabchifar A, Dehpour AR, Pirali Hamedani M, Shafiee A (2002) Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloroimidazolyl substituents. Arzneim Forsch Drug Res 52:21-26
2. Baraldi P, Garuti L, Leoni A, Cacciari B, Budriesi R, Chiarini A (1993) Synthesis and cardiodepressant activity of dialkyl 1,4- dihydro-2,6-dimethyl-4- (pentatomic-heteroaryl)-3,5-pyridinedicarboxylates. Drug Des Discov 10:319-329
3. Bikker JA, Weaver DF (1992) Theoretical studies applicable to the design of novel anticonvulsants: an AM1 molecular orbital structure-activity study of dihydropyridine calcium channel antagonists. Can J Chem 70:2449-2460
4. Bolger GB, Gengo P, Klochowski R, Luchovski E, Siegel H, Janis RA, Triggle AM, Triggle DJ (1983) Characterization of binding of the Ca2? channel antagonist, [3H] nitrendipine to guinea pig ileal smooth muscle. J Pharm Exp Ther 225:291-309
5. Clemens RJ, Hyatt JA (1985) Acetoacetylation with 2,2,6-trimethyl- 4H-1,3-dioxin-4-one: a convenient alternative to diketene. J Org Chem 50:2431-2433
6. Fassihi A, Velazquez C, Knaus EE (2004) Synthesis of dialkyl 1,4- dihydro-2,6-dimethylpyridine-3,5-dicarboxylates and alkyl 1,4- dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylates possessing a C-4 2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl (uracil) substituent to determine calcium channel modulation structureactivity relationships. J Heterocycl Chem 41:263-266
7. Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR, Sabet R, Alborzi A, Miri R, Pourabbas B, Mardaneh J, Mousavi P, Moeineefard B, Sadeghi H (2009) Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5- bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. Eur J Med Chem 44:3253-3258
8. Fleckenstien A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149-166
9. Frisch MJ, Trucks MJ, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JA, Stratmann JR, Burant JC et al. (1998) Gaussian 98, Revision A.7. Gaussian, Inc. Pittsburgh
10. Gaggelli E, Marchettini N, Valensin G (1987) Nuclear magnetic resonance investigation of calcium-antagonist drugs. Part 1. Conformational and dynamic features of nimodipine 3-[(2- methoxyethoxy)carbonyl]-5-(isopropoxycarbonyl)-4- (3-nitrophenyl)- 2,6-dimethyl-1,4-dihydropyridine in [2H6]dimethylsulphoxide. J Chem Soc Perkin Trans 2:1707-1711
11. vGoldmann S, Stoltefuss J (1991) 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew Chem Int Ed Engl 30:1559-1578
12. Guadio AC, Corolkovas A, Takahata Y (1994) Conformational analysis of the 1,4-dihydropyridines linking the structural aspects to the biological binding event: a study of the receptorsite conformation. J Mol Struct (Theochem) 303:255-263
13. Hantzsch A (1882) Uber die synthese pyridinartiger verbindungen aus acetessigather and aldehydammoniak. Justus Lie-bigs Ann Chem 215:1-82
14. Hemmateenejhad B, Miri R, Edraki N, Khoshneviszadeh M, Shafiee A (2007) Molecular modeling and QSAR analysis of some 4,5-dichloroimidazolyl-1,4-DHP- based calcium channel blockers. J Iran Chem Soc 4:182-193
15. Hemmateenejhad B, Miri R, Safarpour MA, Khoshneviszadeh M, Edraki N (2005) Conformational analysis of some new derivatives of 4-nitroimidazolyl-1,4- dihydropyridine-based calcium channel blockers. J Mol Struct (Theohem) 717:139-152
16. HyperChem, Release 7.0 for Windows, Molecular Modeling System: HyperCube, 2002. Visit Hyperchem official website at http://www. hyperchem.com
17. Klegeris A, Liutkevicius E, Mikalauskiene G, Duburs G, McGeer PL, Klusa V (2002) Anti-inflammatory effects of cerebrocrst in a model of rat paw edema and on mononuclear THP-1 cells. Eur J Pharmacol 441:203-208
18. Langs DA, Triggle DJ (1985) Conformational features of calcium channel agonist and antagonist analogs of nifedipine. Mol Pharmacol 27:544-548
19. Li A, Moro S, Melman N, Ji X, Jacobson KA (1998) Structureactivity relationships and molecular modeling of 3,5-diacyl-2,4- dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 41:3186-3201
20. Liepina I, Blanco M, Duburs G, Liwo A (1997) Spatial structure of dihydropyridines and similarity of dihydropyridines with some amino acids. Mol Eng 7:401-427
21. Mahmoudian M, Richard WG (1986) A conformational distinction between dihydropyridine calcium agonists and antagonists. J Chem Soc Chem Commun 10:739-741
22. Matsubara M, Hasegawa K (2005) Benidipine, a dihydropyridine- calcium channel blocker, prevents lysophosphatidylcholineinduced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 178:57-66
23. Memarian HR, Sabzyan H, Abdoli-Senejani M (2007) Conformational analysis of some unsymmetrically substituted 1,4-dihydropyridines. J Mol Struct (Theohem) 813:39-47
24. Meyer H, Bossert F, Wehinger E, Stoepel K, Vater W (1981) Synthesis and comparative pharmacological studies of 1,4- dihydro-2,6-dimethyl-4-(3- nitrophenyl)pyridine-3,5-dicarboxylates with non-identical ester functions. Arzneim Forsch Drug Res 31:407-409
25. Miri R, Howlett SE, Knaus EE (1997) Synthesis and calcium channel modulating effects of isopropyl 1,4-dihydro-2,6-dimethyl-3- nitro-4-(thienyl)-5- pyridinecarboxylates. Arch Pharm Pharm Med Chem 330:290-294
26. Nguyen JT, Velazquez CA, Knaus EE (2005) Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structureactivity relationships and nitric oxide release. Bioorg Med Chem 13:1725-1738
27. Pourmoread F, Hadizadeh F, Shafiee A (1997) Synthesis and calcium channel antagonist activity of 4-imidazolyl-1,4-dihy-dropyridines. Pharm Sci 3:165-168
28. Ramusino MC, Vari MR (1999) Force field and semiempirical MO conformational analysis of dihydropyridine calcium-channel antagonists. J Mol Struct (Theohem) 492:257-268
29. Rovnyak G, Anderson N, Gougoutas J, Hedberg A, Kimball SD, Malley M, Moreland S, Porubcan M, Pudzianowski A (1988) Studies directed towards ascertaining the active conformation of 1,4-dihydropyrimidine calcium entry blockers. J Med Chem 31:936-944
30. Rovnyak GC, Atwal KS, Hedberg A, Kimball SD, Moreland S, Gougoutas JZ, O'Reilly BC, Schwartz J, Malley MF (1992) Dihydropyridine calcium channel blockers: basic 3-substituted 4-aryl-1,4-dihydro-pyridine-5-carboxylic acid esters, potent antihypertensive agent. J Med Chem 35:3254-3263
31. Shafiee A, Miri R, Dehpour AR, Soleymani F (1996) Synthesis and calcium channel antagonist-activity of nifedipine analogues containing nitroimidazolyl substituents. Pharm Sci 2:541-543
32. Shafiee A, Rastkary N, Jorjani M (2002) Synthesis and calcium channel antagonist-activity of 1,4-dihyropyridine derivatives containing 4-nitroimidazolyl substituents. Arzneim Forsch 52:537-542
33. Shah A, Gaveriya H, Motohashi N, Kawase M, Saito S, Sakagami H, Satoh K, Tada Y, Solymosi A, Walfard K, Molnar K (2000) 3,5- Diacetyl-1,4- dihydropyridines synthesis and MDR reversal in tumor cells. Anticancer Res 20:373-377
34. Triggle DG (1992) Biochemical and pharmacologic differences among calcium channel antagonists: clinical implication. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Befus, Philadelphia, p I
35. Triggle AM, Shefter E, Triggle DJ (1980) Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy- 4-[2-nitro-3-cyano-4- (dimethylamino)- and 2,3,4,5,6-pentafluorophenyl]- 1,4-dihydropyridine. J Med Chem 23:1442-1445
36. Zarghi A, Derakhshandeh K, Roshanzamir F (2002) Synthesis and calcium channel antagonist-activity of new 1,4-dihyropyridines containing nitrobenzylimidazolyl substituent. Boll Chim Farmac 141:15-20
37. Zarghi A, Sadeghi H, Fassihi A, Faizi M, Shafiee A (2003a) Synthesis and calcium antagonist activity of 1,4-dihydropyridines containing phenylaminoimidazolyl substituents. Il Farmaco 58: 1077-1081
38. Zarghi A, Abdollahnejad R, Faizi M, Fassihi A (2003b) Synthesis and calcium blocking activity of new 1,4-dihydropyridines containing benzylthioimidazole. Boll Chim Farmac 142:175-179